CEL-SCI CORPORATION Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CEL-SCI CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2021-12-31 was $29.84K, a 26.90% increase year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $464.16K, a 67.92% increase year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $138.79K, a 178.14% increase year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2020-12-31 was $23.51K.
- CEL-SCI CORPORATION stock issued during period, value, stock options exercised for fiscal 2022 was $29.84K, a 96.00% decline from fiscal 2021.
- CEL-SCI CORPORATION stock issued during period, value, stock options exercised for fiscal 2021 was $746.23K, a 120.56% increase from fiscal 2020.
- CEL-SCI CORPORATION stock issued during period, value, stock options exercised for fiscal 2020 was $338.33K, a 124.83% increase from fiscal 2019.
- CEL-SCI CORPORATION stock issued during period, value, stock options exercised for fiscal 2019 was $150.48K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2022-09-30 | $29.84K 10-K · filed 2023-12-21 | |
| 2021-12-31 | $29.84K 10-Q · filed 2023-08-10 | |
| 2021-09-30 | $746.23K 10-K · filed 2022-12-27 | |
| 2021-06-30 | $464.16K 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $138.79K 10-Q · filed 2022-08-12 | |
| 2020-12-31 | $23.51K 10-Q · filed 2022-08-12 | |
| 2020-09-30 | $338.33K 10-K · filed 2021-12-21 | |
| 2020-06-30 | $276.42K 10-Q/A · filed 2020-12-31 | |
| 2020-03-31 | $49.90K 10-Q/A · filed 2020-12-31 | |
| 2019-09-30 | $150.48K 10-K · filed 2020-12-29 | |
| 2019-06-30 | $97.29K 10-Q/A · filed 2020-12-31 | |
| 2012-09-30 | $2.66M 10-K · filed 2013-12-27 | |
| 2011-09-30 | $679.59K 10-K · filed 2013-12-27 | |
| 2010-09-30 | $6.31M 10-K · filed 2012-12-14 | |
| 2009-09-30 | $8.68M 10-K · filed 2011-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |